论文部分内容阅读
目的:分析研究慢性肾小球肾炎合并慢性乙型肝炎临床治疗体会。方法:选取2008年8月-2011年1月在我院接收的患有慢性肾小球肾炎合并慢性乙型肝炎的病人一共有42例,对42例病人采取霉酚酸酯、拉米夫定以及泼尼松联合治疗,对其治疗效果给予分析研究。结果:临床治疗以后,病人尿蛋白明显要比治疗之前明显下降。Alb在临床疗程第24周已经恢复正常水平。临床治疗以后,甘油三酯和血胆固醇显著降低。Scr在第24周以及第36周的时候明显降低。ALT比较治疗之前有显著下降。本文一共42例病人,其中完全缓解21例,占总体的50%;部分缓解15例,占总体的35.71%;无效6例,占总体的14.28%,临床总有效率为85.71%。在整个临床治疗期间,出现呕吐以及恶心1例,占总体的2.38%;继发性肺部感染3例,占总体的7.14%;白细胞下降1例,占总体的2.38%;不良反应发生率为11.9%。然而42例患者都没有停止治疗,通过对症处理以后明显缓解。结论:慢性肾小球肾炎合并慢性乙型肝炎采取霉酚酸酯、拉米夫定以及泼尼松联合治疗,可以使临床疗效明显提高,并不良反应较低,具有临床推广价值。
Objective: To analyze the clinical experience of chronic glomerulonephritis combined with chronic hepatitis B Methods: A total of 42 patients with chronic glomerulonephritis and chronic hepatitis B received in our hospital from August 2008 to January 2011 were selected. Forty-two patients were treated with mycophenolate mofetil, lamivudine And prednisone combination therapy, to analyze the treatment effect. Results: After clinical treatment, the urinary protein in patients obviously decreased obviously compared with that before treatment. Alb returned to normal levels at week 24 of the clinical course of treatment. After clinical treatment, triglycerides and blood cholesterol were significantly reduced. Scr was significantly reduced at Weeks 24 and 36. ALT decreased significantly before treatment. In this paper, a total of 42 patients, of which 21 cases of complete remission, accounting for 50% of the total; partial remission in 15 cases, accounting for 35.71% of the total; ineffective in 6 cases, accounting for 14.28% of the overall, the total effective rate was 85.71%. During the whole clinical treatment, vomiting and nausea occurred in 1 case, accounting for 2.38% of the total; 3 cases of secondary pulmonary infection, accounting for 7.14% of the total; leukopenia in 1 case, accounting for 2.38% of the overall; adverse reactions were 11.9%. However, 42 patients did not stop treatment, after symptomatic treatment significantly relieved. Conclusion: Combined treatment of mycophenolate mofetil, lamivudine and prednisone in patients with chronic glomerulonephritis and chronic hepatitis B can improve the clinical curative effect and lower adverse reactions, which has the clinical value of popularization.